Macrogenics, Inc.
🏢 View company profile →128Patents
119Active
128Granted
57Portfolio score
Filing activity: May 29, 2003 → Aug 8, 2022 · 35 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7355008B2 | Identification and engineering of antibodies with variant Fc regions and methods of using same | Physics | 217 | Expired |
| US7632497B2 | Engineering Fc Antibody regions to confer effector function | Chemistry; Metallurgy | 146 | Expired |
| US7960512B2 | Identification and engineering of antibodies with variant Fc regions and methods of using same | Chemistry; Metallurgy | 122 | Expired |
| US7425619B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 89 | Expired |
| US8946387B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 79 | Active |
| US8217147B2 | Identification and engineering of antibodies with variant Fc regions and methods of using same | Chemistry; Metallurgy | 70 | Active |
| US8003774B2 | Identification and engineering of antibodies with variant Fc regions and methods of using same | Physics | 67 | Active |
| US8193318B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 66 | Active |
| US7521542B2 | Humanized FcγRIIB-specific antibodies and methods of use thereof | Chemistry; Metallurgy | 64 | Expired |
| US8192737B2 | Identification and engineering of antibodies with variant Fc regions and methods of using same | Physics | 62 | Active |
| US9822181B2 | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof | Chemistry; Metallurgy | 57 | Active |
| US7351803B2 | CD16A binding proteins and use for the treatment of immune disorders | Chemistry; Metallurgy | 57 | Expired |
| US8216574B2 | Engineering Fc antibody regions to confer effector function | Chemistry; Metallurgy | 55 | Active |
| US8187593B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 52 | Active |
| US7700100B2 | FcγRIIB fusion proteins and compositions thereof | Chemistry; Metallurgy | 49 | Active |
| US8044180B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 44 | Active |
| US8133982B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 43 | Active |
| US7786270B2 | Humanized FcγRIIB-specific antibodies and methods of use thereof | Physics | 43 | Active |
| US7112439B2 | Dual expression vector system for antibody expression in bacterial and mammalian cells | Chemistry; Metallurgy | 42 | Expired |
| US9096877B2 | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use | Chemistry; Metallurgy | 40 | Active |
| US8216579B2 | Humanized FcγRIIB-specific antibodies and methods of use thereof | Physics | 39 | Active |
| US9587021B2 | CD3-binding molecules capable of binding to human and non-human CD3 | Emerging Cross-Sectional Technologies | 27 | Active |
| US8652466B2 | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting | Chemistry; Metallurgy | 26 | Active |
| US8802091B2 | Antibodies reactive with B7-H3 and uses thereof | Chemistry; Metallurgy | 26 | Active |
| US9150656B2 | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof | Chemistry; Metallurgy | 25 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.